$ATOS News

Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Enters Securities Purchase Agreement With Institutional Investors For 1,363,638 Shares

Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment

CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular Disease

Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Atossa Therapeutics To Host Virtual KOL Event Focused On Evolving Clinical And Translational Data Supporting Development Of (Z)-Endoxifen As Potential Next-Gen Endocrine Therapy Backbone Across Multiple ER-Positive Breast Cancer Settings

ATOS: Initiating Coverage of Atossa Therapeutics; Endoxifen’s Expanding Opportunity from Oncology to Orphan Disease

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Atossa Therapeutics Announces FDA Rare Pediatric Disease Designation To (Z)-endoxifen For The Treatment Of McCune-Albright Syndrome In Females

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service

HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25